Open Access 01.12.2016 | Erratum
Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Erschienen in: Trials | Ausgabe 1/2016
Unfortunately, the original version of this article [1] contained a few formatting errors which have been corrected via an update. In the eighth paragraph of the background there was an error. The original read as, “A phase II study evaluating the combination of nab-paclitaxel plus carboplatin as 199 first-line treatment for mTNBC is currently under way [31].” But should have read as “A phase II study evaluated the combination of nab-paclitaxel plus carboplatin a first-line treatment for mTNBC [31].”
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.